Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
Research type
Research Study
Full title
Comparison of abatacept with tumor necrosis factor inhibitors in the treatment of rheumatoid arthritis pain: A phase IV trial
IRAS ID
275063
Contact name
Nidhi Sofat
Contact email
Sponsor organisation
St George's, University of London
Eudract number
2019-004468-23
Duration of Study in the UK
3 years, 0 months, 4 days
Research summary
Research Summary
Rheumatoid arthritis (RA) is the most common form of arthritis worldwide, with a prevalence of 1-2%. With the advent of biologic agents for the treatment of active rheumatoid arthritis (RA), clinicians managing patients with RA have a wide range of treatments available to control their active disease. A challenge for RA management in the clinic is to stratify patients for the most appropriate treatment at the correct time to achieve optimal disease control and to maintain the patient in remission for as long as possible. In the clinic, many disease modifying anti-rheumatic drugs (DMARDs) are effective at achieving suppression of inflammation, but pain remains a key issue in RA and in some patients treated even with biologic agents, pain control remains an unaddressed issue. In this study, we will be comparing the pain profile of people with rheumatoid arthritis who are receiving different biologic treatments for their pain. If one treatment is shown to be more effective in treating pain than the other, it would be useful to help plan future treatments for pain in people with rheumatoid arthritis.
REC name
East of England - Cambridgeshire and Hertfordshire Research Ethics Committee
REC reference
19/EE/0382
Date of REC Opinion
10 Feb 2020
REC opinion
Further Information Favourable Opinion